SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice

被引：0
|
作者：
John Wilding
Kevin Fernando
Nicola Milne
Marc Evans
Amar Ali
Steve Bain
Debbie Hicks
June James
Philip Newland-Jones
Dipesh Patel
Adie Viljoen
机构：
[1] University of Liverpool,Obesity and Endocrinology Research
[2] North Berwick Health Centre,Department of Diabetes
[3] CODES (COmmunity Diabetes Education and Support),Diabetes Research Unit Cymru
[4] University Hospital Llandough,Department of Diabetes and Endocrinology
[5] Oakenhurst Medical Practice,Department of Metabolic Medicine/Chemical Pathology
[6] Swansea University,undefined
[7] Barnet,undefined
[8] Enfield and Haringey Mental Health Trust,undefined
[9] University Hospitals of Leicester NHS Trust,undefined
[10] University Hospitals Southampton NHS Foundation Trust,undefined
[11] Royal Free NHS Foundation Trust,undefined
[12] Lister Hospital,undefined
来源：
Diabetes Therapy | 2018年 / 9卷
关键词：
Clinical guidance; Glucose-lowering medicines; Oral glucose-lowering medicines; Prescribing tools; Risk/benefit; SGLT2 inhibitors; Therapy choice; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1757 / 1773
页数：16
相关论文
共 50 条
  • [41] Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 Diabetes
    Mannucci, Edoardo
    Mangia, Pier Paolo
    Pradelli, Lorenzo
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2020, 21 : 3 - 20
  • [42] The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes
    Pafili, K.
    Maltezos, E.
    Papanas, N.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (10) : 1133 - 1152
  • [43] SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus
    d'Emden, Michael
    Amerena, John
    Deed, Gary
    Pollock, Carol
    Cooper, Mark E.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 136 : 23 - 31
  • [44] Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
    Evans, Marc
    Hicks, Debbie
    Patel, Dipesh
    Patel, Vinod
    McEwan, Phil
    Dashora, Umesh
    DIABETES THERAPY, 2020, 11 (01) : 37 - 52
  • [45] SGLT2 inhibitors and renal complications in type 1 diabetes
    Petrie, John R.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (10): : 803 - 805
  • [46] Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
    Marc Evans
    Debbie Hicks
    Dipesh Patel
    Vinod Patel
    Phil McEwan
    Umesh Dashora
    Diabetes Therapy, 2020, 11 : 37 - 52
  • [47] Effect of SGLT2 inhibitors on anemia and their possible clinical implications
    Cases, Aleix
    Cigarran, Secundino
    Gorriz, Jose Luis
    Nunez, Julio
    NEFROLOGIA, 2024, 44 (02): : 165 - 172
  • [48] Type 2 Diabetes: SGLT2 Inhibitors and DPP4 Inhibitors in Comparison
    Simon, Annika
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2023, 148 (16) : 1002 - 1002
  • [49] An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials
    Adeghate, Ernest
    Mohsin, Sahar
    Adi, Faisal
    Ahmed, Fares
    Yahya, Ali
    Kalasz, Huba
    Tekes, Kornelia
    Adeghate, Ernest A.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (09) : 811 - 820
  • [50] SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes
    Singhal, Rohit
    Hechanova, Lisa Aimee
    CURRENT CARDIOLOGY REPORTS, 2022, 24 (03) : 183 - 189
12345